Phase I Trial of OPB-111077 in Combination With Decitabine for the Treatment of AML Refractory to or Ineligible for Intensive Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2019
At a glance
- Drugs Decitabine (Primary) ; OPB 111077 (Primary)
- Indications Myeloid leukaemia
- Focus Adverse reactions
- 02 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Dec 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
- 21 Dec 2018 Status changed from suspended to recruiting.